GE HealthCare Technologies Inc. - Common Stock (GEHC)
63.47
+2.13 (3.47%)
NASDAQ · Last Trade: May 9th, 1:41 PM EDT
Detailed Quote
Previous Close
61.34
Open
62.51
Bid
63.01
Ask
63.96
Day's Range
62.00 - 63.49
52 Week Range
58.75 - 89.77
Volume
8,357,229
Market Cap
28.82B
PE Ratio (TTM)
13.11
EPS (TTM)
4.8
Dividend & Yield
0.1400 (0.22%)
1 Month Average Volume
5,593,968
Chart
About GE HealthCare Technologies Inc. - Common Stock (GEHC)
GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator focused on improving patient outcomes through advanced healthcare solutions. The company develops and manufactures a wide range of diagnostic imaging systems, monitoring devices, and healthcare IT services that empower healthcare providers to deliver accurate and efficient patient care. Through its commitment to innovation, GE HealthCare supports clinicians and patients by providing tools that enhance diagnostic capabilities, streamline workflows, and facilitate data-driven decision-making in an increasingly complex healthcare environment. Read More
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
GE HealthCare’s first quarter was marked by strong revenue growth from its pharmaceutical diagnostics and imaging businesses, as well as robust services dema...
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 7....
GE HealthCare (Nasdaq: GEHC) announced today a strategic evolution to its operations and executive leadership team to help shape the company’s next chapter of growth and better serve patients and customers globally. The changes will also position the company to enhance execution, accelerate innovation, and create efficiencies. These changes are effective immediately.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) will be reporting earnings this Wednesday before market open. Here’s what to look for....
GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use in adults and pediatric patients aged 2 years and older with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. FDA Fast Track designation expedites the review of new therapeutics and medical imaging agents that have the potential to address significant unmet patient needs.
GE HealthCare (Nasdaq: GEHC) today announced an expanded collaboration with DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The announcement coincides with the Society of Breast Imaging (SBI) Annual Symposium, where GE HealthCare will showcase its latest advancements in breast imaging and women’s health.
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
GE HealthCare today announced a digital integration between the GE HealthCare bkActiv™ intraoperative ultrasound (iUS) system and the Medtronic Stealth AXiS™ surgical navigation system, which is now commercially available to provide real-time advanced imaging during cranial procedures to complement surgical planning and navigation workflows. This integration builds on an existing strategic alliance between the companies to accelerate next-generation technology innovation across the enterprise, which extends the relationship between GE HealthCare’s Surgical Innovations and Medtronic.
